Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT01993498 (CANTO) for Breast Cancer Nos Metastatic Recurrent, Early Lung Cancer is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
Chronic Toxicities Related to Treatment in Patients With Localized Cancer (CANTO) 14,750 Biomarker-Driven Prevention
The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic cancer. Study of the original cohort will be focused on localized breast cancer patients, other localisation in non-metastatic setting will be explored furtherwise, fist of all in lung cancer.
The project will include four specific aims :
- To develop a ...
Selection criteria The cohort will include female patients with non-metastatic breast cancer (stage I-III) without any selection based on their characteristics (except stage) or treatment. They may be included in other concomitant clinical studies.
Patients will have to sign informed consent an...
Show MoreA Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer
- CANTO
- UC-0140/1103 CANTO
- 2011-A01095-36 (Other Identifier) (French Conpetant Authority)
cohort
breast cancer
early lung cancer
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Otherbreast cancer treatment + blood sampling Standard treatment of breast cancer with intervention : samples collection | blood sampling blood samples collection |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Evaluation of chronic toxicity in patients treated for non-metastatic breast cancer | 8 years |
Women,
Aged 18 years and over,
With an invasive breast cancer diagnosed by cytology or histology,
No clinical evidence of metastasis at the time of inclusion,
Untreated including scored for breast cancer surgery in progress,
Patient receiving a social security system,
Patient mastering the French language,
Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage.
(Since february 2022) Patient :
- Age < 45 years at diagnostic
- Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-
- Or Eligible to Pembrozilumab, Olaparib, TDM1, Abemaciclib or Ribociclib
- Metastatic breast cancer,
- Local recurrence of breast cancer,
- History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,
- Already received treatment for breast cancer ongoing,
- Blood transfusion performed for less than six months,
- Persons deprived of liberty or under supervision (including guardianship).
CANTO - Lung
Inclusion Criteria:
- Aged 18 years and over, Having lung cancer diagnosed by cytology or histology or suspected cancer of the lung,
- Tumor cTX to cT4, cN0-3,
- No clinical evidence of metastasis at the time of inclusion (patients with metastases on extension assessment within 6 months following diagnosis will be removed from the study),
- Eligible for curative treatment by surgery or radiotherapy * (note patients treated with exclusive chemotherapy, exclusive radiotherapy or exclusive stereotactic radiotherapy will be out of study)
- Lack of treatment received for current lung cancer, including surgical treatment
- Patient benefiting from a social protection scheme,
- Patient mastering the French language,
- Free and informed consent for additional biological samples, the different questionnaires and the collection of information on resource consumption.
Exclusion Criteria:
- Metastatic lung cancer,
- Local relapse of lung cancer,
- History of cancer within 3 years prior to study entry other than basal cell cutaneous or epithelioma in situ of the cervix,
- Treatment already received for current lung cancer,
- Blood transfusion carried out less than 6 months ago,
- Persons deprived of liberty or under guardianship (including curatorship).
UNICANCER